Cardiac device therapy has significantly evolved since the introduction of the first implantable pacemaker and the subsequent ...

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior ...

Company's growing data ecosystem supports the development of large data models for its future predictive technologies and Cardiac AI cloud platform Company has analyzed over 360 Billion heartbeats and ...

Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform ...

A University of Houston pharmacology researcher and expert in cardiac development has identified a new cause of - and repair ...

A recent Nature study uses a combination of single-cell ribonucleic acid (scRNA)-sequencing and high-resolution multiplexed error-robust fluorescence in situ hybridization (MERFISH) to better ...

Researchers at Korea University applied magnetic torque stimulation to stem cell-derived cardiac organoids, activating ...

The French clinical stage company focused on cardiac innovation received the funds from a Series C funding round and the EC’s Med4Cure innovation fund.

Heart disease remains the leading cause of death worldwide, yet progress in understanding and treating cardiac disorders is limited by the shortcomings of existing experimental models. Traditional ...